Mirna Therapeutics announced that it has added two scientific advisors, Daniel Von Hoff and Steven McKnight.
Von Hoff is currently director of translational research at the Translational Genomics Research Institute and CSO for US Oncology.
McKnight is professor and chairman of biochemistry at the University of Texas Southwestern Medical Center and currently sits on the scientific advisory board of the Howard Hughes Medical Institute.
Regulus Therapeutics has named Zachary Zimmerman as its director of business development.
In this role, he will be responsible for business development and licensing, as well as managing external collaborations and communications, according to Regulus.
Zimmerman previously served in the business development group of Alnylam Pharmaceuticals, one of Regulus' two parent firms. Prior to that, he was a senior research analyst for IDC's life sciences practice.
Miragen Therapeutics said that it has established its scientific advisory board.
Heading the board is Miragen co-founder Eric Olson, who is also a researcher at the University of Texas Southwestern Medical Center. Also on the SAB are University of Massachusetts Medical School investigator Victor Ambros; company co-founder Michael Bristow, who is also a researcher at the University of Colorado Cardiovascular Institute at the UC Denver School of Medicine; Thomas Cech, a Nobel Laureate and professor at UC Boulder; and Stephanie Dimmeler, a professor at the University of Frankfurt.
Also joining the SAB are Douglas Mann, professor at Washington University School of Medicine, and Jeffery Molkentin, professor at the Cincinnati Children's Hospital Medical Center of the University of Cincinnati.